Company description

Recipharm is a leading contract development and manufacturing organisation (CDMO) headquartered in Stockholm, Sweden. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering for our customers. Employing around 6,000 people, we are focused on supporting pharmaceutical companies with our full service offering, taking products from early development through to commercial production. For over 20 years we have been there for our clients throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again. Despite our growing global footprint, we conduct our business as we always have and continue to deliver value for money with each customer’s needs firmly at the heart of all that we do. That’s the Recipharm way. For more information visit www.recipharm.com

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Formulation development |Custom Manufacturing |Contract Services - Contract Services More

Upcoming events

13 oct 2020

CPhI Worldwide 2020

13 - 15 October 2020 Milan, Italy Visit us at stand 2C43 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 121D32 See our Exhibitor Profile   See full Exhibitor List

News about Recipharm

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more

20 Feb 2020

Recipharm expects cost synergies from Consort purchase within 18 months

Recipharm expects cost synergies of SEK 125 million (USD 12 million) from its recent acquisition of UK drug delivery firm Consort Medical and should realise them within the next 18 months, the Swedish contract research and development organisation (CDMO) said in an earnings call Thursday.

Read more

6 Feb 2020

Recipharm acquisition to make it a top 5 global CDMO?

CEO says the acquisition of Consort Medical will help to create a leading advanced delivery systems company.

Read more

9 Dec 2019

Recipharm investment strengthens its inhalation development service

Installation of a SprayVIEW system will help the CDMO to support customers in both innovative and generic inhalation and nasal product development.

Read more

Contact information




View all contact information